Chronic Neutrophilic Leukemia with V617F JAK2 Mutation

  • Smeeta Gajendra
  • Ritu Gupta
  • Meenal Chandgothia
  • Lalit Kumar
  • Richa Gupta
  • Snehal Motilal Chavan
Case Report

Abstract

Chronic neutrophilic leukemia (CNL) is a rare disease grouped under World health organization classification as chronic myeloproliferative disease. It is a diagnosis of exclusion in patients with sustained mature neutrophilia and splenomegaly with no evidence of other myeloproliferative disease or reactive neutrophilia. V617F JAK 2 mutation has been described in classical myeloproliferative diseases, but its association with CNL has been reported in a few cases. Here in, we describe three cases of CNL with presence of V617F JAK 2 mutation. To distinguish CNL from secondary neutrophilia can be difficult. Detection of the V617F JAK 2 mutation in such scenario can provide a useful diagnostic test to establish the neoplastic nature of the neutrophilia.

Keywords

Chronic myeloproliferative disease Chronic neutrophilic leukemia V617F JAK 2 mutation 

References

  1. 1.
    Reilly JT (2002) Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol 116:10–18PubMedCrossRefGoogle Scholar
  2. 2.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedCrossRefGoogle Scholar
  3. 3.
    Jones AV, Kriel S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168PubMedCrossRefGoogle Scholar
  4. 4.
    Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland G, Tefferi A (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207–1209PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    McLornan DP, Percy MJ, Jones AV, Cross NCP, McMullin MF (2005) Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 90:1696–1697Google Scholar
  6. 6.
    Lea NC, Lim Z, Westwood NB, Amo MJ, Gaken J (2006) Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia. Leukemia 20:1324–1326PubMedCrossRefGoogle Scholar
  7. 7.
    Kako S, Kanda Y, Sato T, Goyam S, Noda N, Shoda E, Oshima K, Inoue M, Izutsu K, Watanabe T, Motokura T, Chiba S, Fukayama M, Kurokawa M (2007) Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol 82:386–390PubMedCrossRefGoogle Scholar
  8. 8.
    Thiele J (2009) Philadelphia chromosome–negative chronic myeloproliferative disease. Am J Clin Pathol 132:261–280PubMedCrossRefGoogle Scholar
  9. 9.
    Chen Q, Lu P, Jones AV, Cross NCP, Silver RT, Wang YL (2007) Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 9:272–276PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker. Blood 88:2410–2414PubMedGoogle Scholar
  11. 11.
    Elliot MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A (2005) WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia 19:313–317CrossRefGoogle Scholar
  12. 12.
    Kralovics  R, Passamonti  F, Buser  AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A  gain-of-function  mutation  of  JAK  in  myeloproliferative  disorders. N  Engl  J  Med 352:1779–1790PubMedCrossRefGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2012

Authors and Affiliations

  • Smeeta Gajendra
    • 1
  • Ritu Gupta
    • 1
  • Meenal Chandgothia
    • 1
  • Lalit Kumar
    • 2
  • Richa Gupta
    • 1
  • Snehal Motilal Chavan
    • 3
  1. 1.Laboratory Oncology UnitDr. B.R.A IRCH, All India Institute of Medical Sciences (AIIMS)New DelhiIndia
  2. 2.Department of Medical OncologyDR. B.R.A IRCH, All India Institute of Medical Sciences (AIIMS)New DelhiIndia
  3. 3.Acton Biotech (I) Pvt. LtdPuneIndia

Personalised recommendations